Izalontamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, izalontamab simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.

**Synonyms:** - Anti-EGFR/HER3 Bispecific Antibody SI-B001 - Anti-EGFR/anti-HER3 Bi-specific Monoclonal Antibody SI-B001 - EGFR/HER3 Bispecific Antibody SI-B001 - HER3 x EGFR SI-B001 - IZALONTAMAB - SI B001 - SI-B001 - SIB001